Answer
Upstaza (eladocagene exuparvovec) is indicated for patients aged 18 months and older with a clinical, molecular, and genetically confirmed diagnosis of aromatic L-amino acid decarboxylase (AADC) deficiency with a severe phenotype.
Sources for this answer
- Upstaza (Eladocagene exuparvovec) solution for infusionPTC Therapeutics Ltd · emc · SmPC §4.1 Therapeutic Indications · Version 7Document updated
Sources checked